Neural Regeneration Research ›› 2026, Vol. 21 ›› Issue (9): 4251-4252.doi: 10.4103/NRR.NRR-D-25-00925

Previous Articles     Next Articles

Targeting the dopaminergic midbrain in Alzheimer’s disease: Therapeutic potential of focusing on specific neural circuits rather than single molecular pathways

Emanuele Claudio Latagliata, Stefano Puglisi-Allegra, Marcello D’Amelio*   

  1. Department of Psychology, International Telematic University Uninettuno, Corso Vittorio Emanuele II, Rome, Italy (Latagliata EC)
    Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS) Neuromed, Via Atinense, Pozzilli, Italy (Latagliata EC, Puglisi-Allegra S)
    Department of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Via del Fosso Di Fiorano, Rome, Italy (D’Amelio M)
    Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, Rome, Italy (D’Amelio M)
  • Online:2026-09-15 Published:2026-05-12
  • Contact: Marcello D’Amelio, PhD, m.damelio@unicampus.it.
  • Supported by:
    This work was supported by the American Alzheimer’s Association [AARG-18–566270; AARG-21–851219], by the Italian Ministry of Health [Research Grant: RF-2018–12365527], by the Italian Ministry of Universities and Research [Prot. 2020Z73J5A] and by Fondazione Roma (Rome, Italy) (to MDA).

PDF

1

Abstract: Alzheimer’s disease (AD) remains one of the most unyielding challenges in neurology. Its complexity and heterogeneity underscore a critical need to explore additional mechanisms that can be targeted in the early stages of the disease to prevent the worsening of functional decline.